These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2176673)

  • 1. Recombinant proteins VP1 and VP3 of hepatitis A virus prime for neutralizing response.
    Gauss-Müller V; Zhou MQ; von der Helm K; Deinhardt F
    J Med Virol; 1990 Aug; 31(4):277-83. PubMed ID: 2176673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenic and immunogenic properties of a hepatitis A virus capsid protein expressed in Escherichia coli.
    Johnston JM; Harmon SA; Binn LN; Richards OC; Ehrenfeld E; Summers DF
    J Infect Dis; 1988 Jun; 157(6):1203-11. PubMed ID: 2836522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic priming with recombinant hepatitis A virus capsid proteins produced in Escherichia coli.
    Powdrill TF; Johnston JM
    J Virol; 1991 May; 65(5):2686-90. PubMed ID: 1850041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and antigenicity of chimeric picornaviruses which express hepatitis A virus (HAV) peptide sequences: evidence for a neutralization domain near the amino terminus of VP1 of HAV.
    Lemon SM; Barclay W; Ferguson M; Murphy P; Jing L; Burke K; Wood D; Katrak K; Sangar D; Minor PD
    Virology; 1992 May; 188(1):285-95. PubMed ID: 1314456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of hepatitis A virus capsid proteins with antisera raised to recombinant antigens.
    Ross BC; Anderson DA
    J Virol Methods; 1991 May; 32(2-3):213-20. PubMed ID: 1651950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoreactivity of human and rabbit antisera to hepatitis A virus.
    Gauss-Müller V; Deinhardt F
    J Med Virol; 1988 Feb; 24(2):219-28. PubMed ID: 2832540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigenic and immunogenic properties of recombinant hepatitis A virus 14S and 70S subviral particles.
    Stapleton JT; Raina V; Winokur PL; Walters K; Klinzman D; Rosen E; McLinden JH
    J Virol; 1993 Feb; 67(2):1080-5. PubMed ID: 7678298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the VP3-VP1 sequence of foot-and-mouth disease virus in Escherichia coli.
    Rossetti ML; Raupp RM; Farias SE; Ferreira LF; Zaha A
    Braz J Med Biol Res; 1993 Jun; 26(6):591-603. PubMed ID: 7504968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response to hepatitis A virus capsid proteins after infection.
    Wang CH; Tschen SY; Heinricy U; Weber M; Flehmig B
    J Clin Microbiol; 1996 Mar; 34(3):707-13. PubMed ID: 8904442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of hepatitis A virus capsid sequences in insect cells.
    Harmon SA; Johnston JM; Ziegelhoffer T; Richards OC; Summers DF; Ehrenfeld E
    Virus Res; 1988 May; 10(2-3):273-80. PubMed ID: 2842974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and immunogenic analysis of recombinant polypeptides derived from capsid protein VP1 for developing subunit vaccine material against hepatitis A virus.
    Jang KO; Park JH; Lee HH; Chung DK; Kim W; Chung IS
    Protein Expr Purif; 2014 Aug; 100():1-9. PubMed ID: 24816194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of immunogenic hepatitis A virus particles by recombinant baculoviruses.
    Rosen E; Stapleton JT; McLinden J
    Vaccine; 1993; 11(7):706-12. PubMed ID: 8393604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The production of human parvovirus capsid proteins in Escherichia coli and their potential as diagnostic antigens.
    Rayment FB; Crosdale E; Morris DJ; Pattison JR; Talbot P; Clare JJ
    J Gen Virol; 1990 Nov; 71 ( Pt 11)():2665-72. PubMed ID: 1701479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of amino acids located in the antibody binding sites of human hepatitis A virus.
    Nainan OV; Brinton MA; Margolis HS
    Virology; 1992 Dec; 191(2):984-7. PubMed ID: 1280386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of the immunogenicity of a synthetic peptide bearing a VP3 epitope of hepatitis A virus.
    Pintó RM; González-Dankaart JF; Sánchez G; Guix S; Gómara MJ; García M; Haro I; Bosch A
    FEBS Lett; 1998 Oct; 438(1-2):106-10. PubMed ID: 9821968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of fusion proteins containing antigenic determinants of foot-and-mouth disease virus.
    Broekhuijsen MP; Blom T; Kottenhagen M; Pouwels PH; Meloen RH; Barteling SJ; Enger-Valk BE
    Vaccine; 1986 Jun; 4(2):119-24. PubMed ID: 2425505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regions of poliovirus protein VP1 produced in Escherichia coli induce neutralizing antibodies.
    Hoatlin ME; Kew OM; Renz ME
    J Virol; 1987 May; 61(5):1442-7. PubMed ID: 3033273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure of the hepatitis A virion: peptide mapping of the capsid region.
    Wheeler CM; Robertson BH; Van Nest G; Dina D; Bradley DW; Fields HA
    J Virol; 1986 May; 58(2):307-13. PubMed ID: 3009847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of neutralizing antibodies by poliovirus capsid polypeptides VP1, VP2 and VP3.
    van der Marel P; Hazendonk TG; Henneke MA; van Wezel AL
    Vaccine; 1983 Dec; 1(1):17-22. PubMed ID: 6099638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of hepatitis A virus cDNA in Escherichia coli: antigenic VP1 recombinant protein.
    Ostermayr R; von der Helm K; Gauss-Müller V; Winnacker EL; Deinhardt F
    J Virol; 1987 Nov; 61(11):3645-7. PubMed ID: 2822970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.